

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number  
**WO 03/103629 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 9/00**,  
47/26, 47/38, 47/36

(21) International Application Number: PCT/IB03/02446

(22) International Filing Date: 4 June 2003 (04.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
P-200201440 10 June 2002 (10.06.2002) ES

(71) Applicant (for all designated States except US): **LABORATORIOS VITA, S. A.** [ES/ES]; Av. Barcelona, 69, E-08970 Sant Joan Despi (ES).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SEGADO FERRAN, Javier** [ES/ES]; C. Mallorca, 620, 4° 2ª, E-08026 Barcelona (ES).

(74) Agents: **PONTI SALES, Adelaida** et al.; C. Consell de Cent, 322, E-08007 Barcelona (ES).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)


— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— with international search report

[Continued on next page]

(54) Title: ORALLY DISINTEGRATING TABLETS AND PROCESS FOR OBTAINING THEM.



(57) Abstract: The tablets comprise: at least 59.5% spray-dried mannitol; active ingredient below or equal to 10%, where at least 90% in weight of the active ingredient has a particle size below 100 µm; microcrystalline cellulose 10-18%, with an average particle size of 50 µm and where at least 99% in weight of microcrystalline cellulose has a particle size below 250 µm; sodium croscarmellose 1-4%; and a lubricant agent 0.5-2%; where, unless specified otherwise, the percentages are expressed in weight of the total weight of the tablet. And also a process comprising: sieving and mixing of components except for the lubricant agent; mixing of all components; and direct compression of the final mixture. The tablets of the invention give lower disintegration times as well as good perception on the tongue after disintegration, and overcome the problem of insufficient mechanical resistance for packaging and transport operations.

WO 03/103629 A1



— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**ORALLY DISINTEGRATING TABLETS AND PROCESS FOR OBTAINING  
THEM**

**Field of the invention**

This invention relates to orally disintegrating tablets,  
5 in other words, tablets for peroral administration which  
disintegrate quickly in the cavity of the mouth, in  
particular in less than 30 seconds, and to the process for  
obtaining them.

10 **Background of the invention**

The development of solid formulas that disintegrate  
quickly in the mouth without requiring water has awoken  
great interest in the advantages this implies for patients  
who have difficulty in swallowing, such as old people,  
15 infants, patients with mental problems and non-cooperative  
patients, as well as the population in general, since it  
makes it possible for the drug to be administered without  
the need for water.

20 In the European Pharmacopoeia 4th edition, Supplement 4.1,  
published in October 2001, orally disintegrating tablets  
are defined as non-coated tablets for placing in the mouth  
which disintegrate quickly before they are swallowed. It  
also establishes 3 minutes as the time under which they  
25 must disintegrate in the disintegration test for tablets  
and capsules, according to the Ph. Eur. 2.9.1. method.

Different technologies have been developed, based on  
alternatives to the conventional processes used for  
30 obtaining tablets, which enable the obtaining of formulas  
that disintegrate quickly in the oral cavity, and which  
are very palatable. The most well-known include those  
which make it possible to obtain oral lyophilisate,  
matrixes by compression of saccharide based shearform  
35 floss particles and films or wafers. However, the

compositions obtained using said technologies have disadvantages to a greater or lesser extent, such as their being highly fragile, extremely sensitive to atmospheric humidity, technologically difficult to obtain and especially costly to produce on an industrial scale.

To simplify the aforementioned technologies and in particular to reduce production costs and overcome the aforementioned disadvantages, the standard tablet production processes have been optimised.

The most frequently used processes for obtaining tablets include:

a) Obtaining tablets by the direct compression of mixtures that contain at least one inorganic excipient that is insoluble in water, for example, calcium phosphate, one or more disintegrants, for example, croscopovidone and optionally, water soluble excipients. Said technology is registered as Ziplets<sup>®</sup> by Eurand and is described in the international application patent WO 9944580. However, the compositions used contain a high percentage of insoluble excipients which leave a high amount of residue in the mouth and jeopardise their palatability.

25

b) Obtaining tablets via the direct compression of mixtures that contain at least a non-direct compression filler, for example, dextrose, mannitol, sorbitol, lactose, and a lubricant. Said technology is registered as Durasolv<sup>®</sup> by Cima, and is described in the patent US 6.024.981.

30

c) Obtaining multiparticulate tablets made up of mixtures of microencapsulated active ingredients and excipients that contain one or several disintegrating agents, one

35

or several hygroscopic agents and a direct compression soluble diluent. Said technology is registered as Flashtab® by Prographarm and is described in the patent EP 0548356.

5

d) Obtaining orally disintegrating tablets that disintegrate in the oral cavity in less than 60 seconds, and which contain spray-dried mannitol, crospovidone and other excipients, by direct  
10 compression. Said technology is described in the patent application WO 00/57857 by Yuhan Corporation.

However, all the above processes for obtaining tablets involve, to a greater or lesser extent, the following  
15 disadvantages:

- A high content of insoluble excipients or microencapsulated active ingredients that give the formula a gritty feel after they have been disintegrated in the oral cavity and,  
20 consequently, problems with palatability.
- Excessively long disintegration times in comparison with oral lyophilisates or wafers, which, in general, dissolve in less than 10 seconds.
- 25 - Insufficient mechanical resistance to resist conventional packaging and transport operations.

#### **Description of the invention**

A first aspect of the present invention is to provide  
30 orally administered tablets that disintegrate quickly in the oral cavity, in particular, in less than 30 seconds, and which can hardly be noticed on the tongue after their disintegration.

35 A second aspect of the present invention is to provide a

process for obtaining said orally disintegrating tablets via direct compression, where direct compression is understood as a manufacturing process that involves sieving, mixing and compression operations only.

5

#### **Detailed description of the invention**

Surprisingly, the present invention has revealed that by using a diluent of high dissolution rate and high compressibility, and limiting the proportion and size of  
10 the particle of the insoluble ingredients, mixtures with optimum compressibility can be obtained. These mixtures enable the obtaining of orally disintegrating tablets which disintegrate in the mouth in less than 30 seconds, preferably less than 20 seconds, once they come into  
15 contact with saliva in the oral cavity, and which are hardly noticed on the tongue.

A further advantage is that the tablets described in the invention have sufficient mechanical resistance to resist  
20 the production and distribution operations, unlike other fast disintegration formulas such as oral lyophilisates, tablets of saccharide based shearform floss and wafers. The tablets of the invention have a friability of below 0.5%, preferably below 0.2%, as specified by Ph. Eur.  
25 2.9.7. These friability values enable packaging in any kind of package using conventional machinery, and do not require any special care to be taken in the intermediate bulk storage of the tablets or in the feed systems used in the packaging operation.

30

As a result, the first aspect of the present invention relates to an orally administered tablet as defined in the attached claims 1 to 11.

A priori, there are no limitations to the active  
35 ingredients in this invention, although the active

ingredients indicated in patients with swallowing difficulties, such as infants or old patients and/or non-cooperative patients, for example, patients with mental problems, are preferential candidates.

5

Of special interest are the active ingredients with dosage preferably below 50 mg per tablet. The preferred compounds are selected from, but not limited to, the following:

anti-ulcer drugs: famotidine; antiemetics: ondansetron,  
10 granisetron, dolasetron, domperidone, metoclopramide;  
antihypertensive drugs: enalapril, losartan, candesartan, valsartan, lisinopril, ramipril, doxazosin, terazosin;  
antihistaminic drugs: loratadine, cetirizine;  
antipsychotic drugs: risperidone, olanzapine, quetiapine;  
15 antidepressants: paroxetine, fluoxetine, mirtazapine;  
analgesics and anti-inflammatory drugs: piroxicam;  
antihypercholesterolemic drugs: simvastatin, lovastatin, pravastatin;  
antimigraine drugs: zolmitriptan, naratriptan, rizatriptan;  
anti-epileptic drugs:  
20 lamotrigine; anti-Parkinson drugs: selegiline, apomorphine;  
anxiolytic drugs: diazepam, lorazepam, zolpidem;  
anti-asthma drugs: zafirlukast, montelukast;  
erection dysfunction agents: sildenafil; both in their free base form and in their acceptable pharmaceutical  
25 salts, hydrates, solvates or isomers.

The orally disintegrating tablets described in the present invention disintegrate in less than 30 seconds, preferably in less than 20 seconds, once they come into contact with  
30 the saliva of the oral cavity. To determine the disintegration time, an alternative *in vitro* method has been standardised which is more discriminating than that which is set forth in Ph. Eur. 2.9.1., together with an *in vivo* disintegration test. The values obtained in both  
35 tests have been seen to be reproducible and are related,

where the *in vivo* results are always lower than those obtained *in vitro* (see Experimental Section, Example 1). The tests used are described below in the "tablet characterisation" section set forth in the Experimental Section of this invention.

Spray-dried mannitol, an excipient which is commercially available, such as Mannogen<sup>TM</sup> EZ spray dried mannitol by SPI Pharma and Pearlitol<sup>®</sup> SD by Roquette, has physical-  
10 chemical properties that make it ideal for constituting the appropriate diluent for this invention. The following is of particular interest:

- It dissolves easily in water (1 in 5.5 parts at 20°C);
- 15 - It dissolves quickly in water (5 g dissolve in approximately 5 s in 150 mL of water at 20°C). This disintegrating rate is much faster than that of direct compression mannitol, that of powder mannitol and other related saccharide excipients. Spray-dried mannitol is  
20 made up fundamentally by the crystalline form  $\alpha$ , unlike the other types of mannitol, which are made up of the  $\beta$  form. Both forms can be easily distinguished using the IR spectrum.
- It has optimum fluidity for direct compression  
25 processes (flowability: 6 seconds and ability to settle: 16-18 ml).
- It is highly compressible (Cohesion Index: 1500 - 2000).
- It has good dilution capacity due to the size and  
30 form of the particle, which makes it possible to accept large amounts of active ingredients that are not easily compressed.
- This is a product with a deformation by  
35 fragmentation when it is subjected to pressure, generating new particle surfaces and becoming

insensitive to the loss of compressibility due to over lubrication with hydrophobic lubricants.

- It is very chemically stable; non-hygroscopic and does not form Maillard reactions with amino groups like other related saccharide excipients.
- It has optimum organoleptic properties due to negative dissolution heat (sense of freshness), its sweetening power of approximately 50% of that of sucrose, and its excellent palatability due to its small particle size.

It has been established that the compounds of the present invention must contain at least 59.5% of spray-dried mannitol.

15

With regard to the dissolving capacity of spray-dried mannitol, in general, it has been established that to guarantee the compressibility and fluidity of the mixture that is to be compressed, the active ingredient content must not exceed 10% in weight of the total weight of the tablet. Also, to guarantee the palatability of the finished product and the uniformity of the mixture, the active ingredient must be a fine powder, where at least 90% in weight of the active ingredient has a particle size of below 100  $\mu\text{m}$ .

To minimise the disintegration time and maximise the mechanical resistance of the tablets of this invention, a disintegration promoter system has been designed, made up of the following:

- Microcrystalline cellulose (e.g. Avicel® PH 101 or Emcocel® 50 M) of average particle size of approximately 50  $\mu\text{m}$ , where at least 99% in weight of microcrystalline cellulose is below 250  $\mu\text{m}$ . The proportion of microcrystalline cellulose is from 10 to

18% in weight of the total weight of the tablet, preferably from 12 to 15%. Said amount makes it possible to significantly improve compressibility, reduce friability and achieve a substantial reduction in disintegration time. Higher quantities have a negative impact on the palatability of the formula and lower quantities worsen the capacity of the disintegration promoter.

- Sodium croscarmellose (e.g. Ac-Di-Sol®) is present in a proportion from 1 to 4% of the total weight of the tablet, preferably from 2 to 3%. Higher quantities have a negative impact on the palatability of the formula and do not offer significant advantages with regard to disintegration rate.

15 - Optionally, a humidity absorbent agent may be added, such as precipitated silica (e.g. Syloid®) in a proportion from 0.1 to 0.5% in weight of the total weight of the tablet, which may counteract the hydrophobicity of certain active ingredients and improve the fluidity of the mixture.

Preferably, said disintegration promoter system should be in a proportion from 14 to 18.5% of the total weight of the mixture.

25

The tablets of this invention may also contain, to improve patient acceptance, a sweetening/flavouring system made up of:

- An artificial sweetener or a combination thereof which must be adapted in accord with the organoleptic properties of the active ingredient. The following may be used, but the list does not exclude other options: aspartame, sodium cyclamate, sodium saccharine, ammonium glycyrrhizinate, neohesperidine

dihydrochalcone. The flavouring agent content is from 0.5 to 2% in weight of the total weight of the tablet.

- A flavouring agent, preferably a microencapsulated powder flavouring on a support that is soluble and which disintegrates in water. The flavouring content is from 0.5 to 2% in weight of the total weight of the tablet.

Optionally, ionic exchange resins or polymers which form complexes with the active ingredients may be added, enabling masking of unpleasant tastes. The following may be used, but the list does not exclude other options: polividone,  $\beta$ -ciclodextrin, potassium polacrilin.

Especially good results regarding the masking of unpleasant tasting active ingredients have been obtained using the system made up of aspartame, ammonium glycyrrhizinate, mentholated flavouring and L-menthol (0.1-0,2% in weight), which due to its refreshing effect has a synergic effect with the spray-dried mannitol and a good tastemasking capacity due to its residual effect. Therefore, the composition of the invention with this sweetening/flavouring system is beneficial in that it avoids the use of costly processes such as microencapsulation or coating the active ingredients in order to mask their bitter taste.

Finally, to facilitate the compression operation, a lubricant agent must be added and, if necessary, an anti-adherent agent in an appropriate proportion. Although the preferred lubricant is magnesium stearate, other less hydrophobic lubricants may be used to counter the hydrophobicity in certain cases of specific active ingredients such as sodium fumarate, polyethylene glycol 6000, sodium lauryl sulphate and a combination of magnesium stearate with sodium lauryl sulphate (9:1) and

sucrose esters. The proportion of lubricant shall be from 0.5 to 2% in weight of the total weight of the tablet. The proportion of anti-adherent agent, such as talcum, colloidal silicon dioxide, shall be from 0.5 to 2% in 5 weight of the total weight of the tablet.

Another advantage is that palatability improves even more if the proportion of insoluble ingredients is below 20%. Insoluble ingredients of the composition of the invention  
10 include: microcrystalline cellulose, sodium croscarmellose, humidity adsorbing agent, lubricant agents, anti-adherent agents and insoluble active ingredients.

15 The present invention shows that it is possible to have a significant influence on the disintegration rate of the tablet by modifying the dimensions and shape of the tablet. In general, the thinner the tablet and the greater its porosity, the sooner the structure of the matrix is  
20 weakened when it comes into contact with saliva, since the disintegration process is produced after wetting all the die via capillary action. Also, any shape which maximises the contact surface with the saliva will produce a significant reduction in disintegration time, obtaining  
25 disintegration values of up to below 20 seconds. The preferred shape of this invention is a flat round bevelled tablet with a thickness from 2.2 to 1.8 mm, though this is not exclusive.

30 Thus, the mixtures of the aforementioned components shall be transformed into orally disintegrating tablets in accord with the process for obtaining them described below and defined in the attached claims 12 to 14.

According to the invention, the tablets have:

35 - A friability below 0.5%, preferably below 0.2 %.

- A disintegration time in the oral cavity of below 30 seconds, preferably below 20 seconds.
- An apparent density from 1.1 to 1.3 g/ml.

5 The apparent density of the tablets is calculated by means of the division of the mass (m) by the volume (.e.g.  $V = \pi \cdot r^2 \cdot h$ , if the tablet is flat and round like the preferable shape proposed in this invention, where r is the radius and h the thickness of the tablet). It has been  
10 shown that the apparent densities of the tablets obtained with the compositions of the present invention correlate to the resistance to breakage of the tablets and to their disintegration time in the mouth. It has also been shown that tablets with apparent densities from 1.1 to 1.3 g/ml  
15 make it possible to guarantee the specifications of friability and disintegration, which is the aim of the present invention.

It has also been observed that in order to guarantee  
20 fulfilment of the specification of the disintegration time in the oral cavity, the tablets should disintegrate in less than 40 seconds in the *in vitro* disintegration test described in the tablet characterisation section of the Experimental Section of the present invention.

25

As mentioned previously, the present invention also relates to a process for obtaining said orally disintegrating tablets comprising direct compression. The tablets described in the invention are obtained by  
30 compression of a powder blend into solid form, which dimensions and shape enable even further minimisation of disintegration time.

In particular, the process for obtaining an orally  
35 administered tablet as previously defined comprises the

following steps:

- i) Sieving and mixing of the components except for the lubricant agent;
- ii) Sieving of the lubricant agent;
- 5      iii) Mixing all the components; and
- iv) Direct compression of the final mixture.

In some cases, sequential mixing processes may be required in order to guarantee the uniformity of the content of the 10 mixture or to guarantee the functionality of certain excipients (e.g. mixtures of active ingredient with polymers for taste masking).

Due to the high compressibility of the compositions of the 15 present invention, it is possible to obtain tablets with appropriate mechanical resistance, applying low pressures during the compression process, preferably from 3 to 10 kN.

20 Mixtures which are considered appropriate for compression are the ones which possess a flowability below or equal to 10 seconds, determined according to the method described in Ph. Eur. 2.9.16 and/or an ability to settle ( $V_{10}-V_{500}$ ) below or equal to 20 ml, determined in accord with Ph. 25 Eur. 2.9.15.

Preferably, the mixture must also possess a preferential cohesion index (CI) of over 700, being CI the slope of the straight line that adjusts the hardness values (Newtons) 30 in accord with the strength of compression (decaNewtons), multiplied by  $10^5$ .

#### **Description of the figures**

Figure 1 shows schematically the *in vitro* disintegration 35 test. In said figure 1, tablet 1 is placed in a Petri dish

2 on a filter paper with 9-10 ml of disintegration medium  
3.

### **Experimental Section**

Particular embodiments are shown by the following examples  
5 without limiting the scope of the invention.

#### **General process:**

- Weigh all components of the formula.
- Sieve, except for the lubricant, through a 0.5 mm  
10 sieve.
- Mix in a Túrbula T2B mixer for 5 minutes.
- Sift the lubricant through a 0.32 mm sieve.
- Mix in a Túrbula T2B mixer for 2 minutes.
- Compress in a machine fitted with the appropriate  
15 compression tools, in accord with specifications of  
established weight, thickness and hardness.

#### **Characterisation of tablets:**

##### **Hardness (N):**

20 This is determined in a Schleuniger 6D durometer using the  
resistance to crushing method set forth in en Ph. Eur.  
2.9.8. The average value and range of the determinations  
are detailed.

##### **Weight (mg):**

25 This is determined by an analytical weighing balance with  
a sample of 10 tablets. The average value and range of  
the determinations are detailed.

##### **Thickness (mm):**

This is determined with a calliper square using a sample  
30 of 10 tablets. The average value and range of the  
determinations are detailed.

##### **Friability (%):**

This is determined in a Pharmatest friability tester using  
35 the method set forth in Ph. Eur. 2.9.7.

**Tensile strength (N/mm<sup>2</sup>) :**

This is calculated based on the average values of hardness and thickness in accord with the formula  $T = 2 \cdot F / \pi \cdot d \cdot h$ ; where "F" is resistance to crushing, "d" is the diameter of the tablet and "h" is the thickness.

**In vitro disintegration test (s) :**

On a 100x10 mm glass Petri dish, place a 90 mm diameter filter paper (reference: WH 1442090) and pour on said dish a volume of 9-10 ml of disintegration medium at room temperature (aqueous solution at 10% (w/w) of cobalt II 6-hydrate chloride). Tilt the dish until all the paper is soaked and there are no air bubbles below it. Immediately after the preparation, place a tablet on the dish and start the chronometer. Observe how the water rises by capillary action and the final point of disintegration is taken to be when the tablet is fully wet. Six tablets are tested on each dish (see figure 1: *in vitro* disintegration test):

**In vivo disintegration test (s) :**

Place the orally disintegrating tablet on the tongue, start the chronometer and actively suck until it is completely disintegrated. Total disintegration is considered to have been reached when the tablet has completely broken down in the mouth, even though there may still be residue to be swallowed. Note down the time in seconds. Perform the test with a maximum of three tablets.

30

**EXAMPLE 1**

A placebo of orally disintegrating tablets was obtained using the general process described initially and the

35

composition given in Table I. Table I gives a summary of the results obtained in the characterisation of the tablets. Tables II and III compile the results obtained in the *in vitro* and *in vivo* disintegration tests by two 5 different analysts.

**Table I: Orally disintegrating placebo tablets**

| Composition for 1000 tablets            |                                 |
|-----------------------------------------|---------------------------------|
| Ingredients                             | quantity (g)                    |
| Spray-dried mannitol                    | 108.0                           |
| Microcrystalline cellulose              | 22.5                            |
| Sodium croscarmellose                   | 4.5                             |
| Aspartame                               | 2.0                             |
| Mint flavouring                         | 2.0                             |
| Magnesium stearate                      | 3.0                             |
| Parameters                              | Values                          |
| Shape                                   | round 9.2 mm,<br>flat, bevelled |
| Average weight (mg)                     | 141.8 (135.2-<br>146.9)         |
| Hardness (N)                            | 21 (15 - 28)                    |
| Thickness (mm)                          | 1.94 (1.85 - 1.99)              |
| Tensile strength (N/mm <sup>2</sup> )   | 0.7                             |
| Friability (%)                          | 0.35                            |
| <i>in vitro</i> disintegration time (s) | See Table II                    |
| <i>in vivo</i> disintegration time (s)  | See Table III                   |

**Table II: *In vitro* disintegration time (seconds)**

| Orally disintegrating placebo tablets<br>Example 1 |           |           |
|----------------------------------------------------|-----------|-----------|
| Num.                                               | ANALYST 1 | ANALYST 2 |
| 1                                                  | 26        | 27        |
| 2                                                  | 32        | 28        |
| 3                                                  | 19        | 23        |
| 4                                                  | 14        | 13        |
| 5                                                  | 12        | 25        |
| 6                                                  | 17        | 30        |
| 7                                                  | 33        | 14        |
| 8                                                  | 14        | 15        |
| 9                                                  | 23        | 21        |
| 10                                                 | 30        | 15        |
| 11                                                 | 22        | 14        |
| 12                                                 | 15        | 24        |
| 13                                                 | 30        | 22        |
| 14                                                 | 12        | 13        |
| 15                                                 | 16        | 17        |
| 16                                                 | 18        | 16        |
| 17                                                 | 14        | 14        |
| 18                                                 | 12        | 29        |
| average                                            | 19.94     | 20.00     |
| s                                                  | 7.34      | 6.09      |
| min                                                | 12        | 13        |
| max                                                | 33        | 30        |

There are no statistically significant differences between individuals when detecting the final point in the *in vitro* disintegration test ( $p=0,9804$ )

Table III: *In vivo* disintegration time (seconds)

| Orally disintegrating placebo tablets Example 1 |           |           |
|-------------------------------------------------|-----------|-----------|
| Num.                                            | ANALYST 1 | ANALYST 2 |
| 1                                               | 13        | 9         |
| 2                                               | 11        | 12        |
| 3                                               | 11        | 14        |
| 4                                               | 17        | 13        |
| 5                                               | 11        | 13        |
| 6                                               | 7         | 11        |
| 7                                               | 10        | 11        |
| 8                                               | 12        | 9         |
| 9                                               | 10        | 9         |
| 10                                              | 16        | 9         |
| average                                         | 11.8      | 11.0      |
| s                                               | 2.94      | 1.94      |
| min                                             | 7         | 9         |
| max                                             | 17        | 14        |

There are no statistically significant differences between individuals when detecting the final point in the *in vivo* disintegration test ( $p=0,4817$ ). However, there are 5 differences between the "*in vivo*" and "*in vitro*" disintegration test ( $p<0,05$ ). In general, the values obtained in the *in vitro* test are higher than those obtained *in vivo*.

#### 10 EXAMPLES 2 TO 6

Five orally disintegrating placebo tablet compounds were prepared to determine the optimum content of the disintegrating system and the proposed diluent, using the general process initially described and with the 15 compositions as detailed in Table IV. The results obtained in the characterisation of the tablets are given in Table V.

Table IV: Orally disintegrating placebo tablets

| Composition for 100 g       |              |      |      |      |      |
|-----------------------------|--------------|------|------|------|------|
| Ingredients                 | Quantity (g) |      |      |      |      |
|                             | Ex. 2        | Ex.3 | Ex.4 | Ex.5 | Ex.6 |
| Spray-dried mannitol        | 84           | 74   | 79   | -    | 81   |
| Direct compression dextrose | -            | -    | -    | 79   | -    |
| Microcrystalline cellulose  | 10           | 20   | 15   | 15   | 15   |
| Sodium croscarmellose       | 5            | 5    | 5    | 5    | 3    |
| Magnesium stearate          | 1            | 1    | 1    | 1    | 1    |

Table V: Characterisation of the tablets in examples 2-6

| Parameters                              | Ex. 2                      | Ex.3        | Ex.4    | Ex.5         | Ex.6    |
|-----------------------------------------|----------------------------|-------------|---------|--------------|---------|
| Shape                                   | Round 9 mm, flat, bevelled |             |         |              |         |
| Average weight (mg)                     | 147.5                      | 146.2       | 144.5   | 151.7        | 148.5   |
| Hardness (N)                            | 26.2                       | 25.0        | 20.7    | 23.4         | 21.9    |
| Thickness (mm)                          | 2.09                       | 2.12        | 2.15    | 2.09         | 2.12    |
| Tensile strength (N/mm <sup>2</sup> )   | 0.9                        | 0.8.        | 0.7     | 0.8          | 0.7     |
| Friability (%)                          | 0.46                       | 0.07        | 0.07    | 0.84         | 0.14    |
| <i>In vitro</i> disintegration time (s) | 24                         | 21          | 19      | 27           | 18      |
| <i>In vivo</i> disintegration time (s)  | 20                         | 12          | 11      | 18           | 13      |
| Palatability                            | Residue                    | Residue (+) | Residue | Residue (++) | Correct |

The results obtained from this series of experiments corroborate the ideal nature of the promoter system of the disintegration proposed in the present invention.

#### 5 EXAMPLE 7

A mixture of orally disintegrating tablets of ondansetron was prepared, using the general process initially described and with the composition given in Table VI. To determine the impact of the shape and dimensions of the  
10 tablet on the disintegration time, the compound was compressed with three different formats. The results obtained are given in Table VII.

Table VI: Orally disintegrating tablets of 8 mg of  
15 ondansetron

| Composition for 100 g      |              |
|----------------------------|--------------|
| Ingredients                | Quantity (g) |
| Ondansetron base           | 5.3          |
| Spray-dried mannitol       | 73.1         |
| Microcrystalline cellulose | 15.0         |
| Sodium croscarmellose      | 3            |
| Aspartame                  | 1.3          |
| Mint flavour               | 1.3          |
| Magnesium stearate         | 1.0          |

Table VII: Characterisation of the tablets in example 7

| Parameters                            | Ex. 7a                         | Ex. 7b                           | Ex. 7c                      |
|---------------------------------------|--------------------------------|----------------------------------|-----------------------------|
| Shape                                 | Round<br>8 mm<br>Flat bevelled | Round<br>9,0 mm<br>Flat bevelled | Round<br>9,0 mm<br>biconvex |
| Average weight (mg)                   | 153.1<br>(151.4-157.8)         | 150.4<br>(147.2-153.8)           | 149.1<br>(147.4-153.2)      |
| Hardness (N)                          | 22.3 (19-29)                   | 21.5 (18-27)                     | 23.1 (20-28)                |
| Thickness (mm)                        | 2.75<br>(2.71-2.8)             | 2.17<br>(2.11-2.2)               | 2.32<br>(2.31-2.4)          |
| Tensile strength (N/mm <sup>2</sup> ) | 0.65                           | 0.7                              | 0.7                         |
| Friability (%)                        | 0.2 %                          | 0.14 %                           | 0.18 %                      |
| In vitro disintegration time (s)      | 34.8 (32-38)                   | 22.9 (19-26)                     | 38.2 (34-41)                |
| In vivo disintegration time (s)       | 20 (18-25)                     | 15 (14-16)                       | 24 (22-27)                  |

It is shown that the flat tablets disintegrate 5 significantly faster than the convex ones and that the thickness also affects disintegration time.

#### EXAMPLE 8

A mixture of orally disintegrating tablets of granisetron 10 was prepared, using the general process initially

described and with the composition and results given in Table VIII.

**Table VIII: Orally disintegrating tablets of 1 mg of 5 granisetron**

| <b>Composition for 100 g</b>            |                            |
|-----------------------------------------|----------------------------|
| <b>Ingredients</b>                      | <b>Quantity (g)</b>        |
| Granisetron base                        | 2.0                        |
| Spray-dried mannitol                    | 75.0                       |
| Microcrystalline cellulose              | 15.0                       |
| Sodium croscarmellose                   | 3.0                        |
| Ammonium glycyrrhizinate                | 0.5                        |
| Aspartame                               | 2.0                        |
| Orange flavour                          | 1.5                        |
| Magnesium stearate                      | 1.0                        |
| <b>Parameters</b>                       | <b>Values</b>              |
| Shape                                   | Round 5 mm, flat, bevelled |
| Average weight (mg)                     | 51.5 (42.4-58.1)           |
| Hardness (N)                            | 23.5 (18-34)               |
| Thickness (mm)                          | 2.02 (1.97-2.08)           |
| Tensile strength (N/mm <sup>2</sup> )   | 1.5                        |
| Friability (%)                          | 0.08                       |
| Apparent density (g/ml)                 | 1.2                        |
| <i>In vitro</i> disintegration time (s) | 16.4 (13-21)               |
| <i>In vivo</i> disintegration time (s)  | 11 (10-14)                 |

#### **EXAMPLE 9**

A mixture of orally disintegrating tablets of risperidone 10 was prepared, using the general process initially described and with the composition and results given in Table IX. The results obtained in the characterisation of the tablets are also given in Table IX.

**Table IX: Orally disintegrating tablets of 1 mg of risperidone**

| <b>Composition for 100 g</b>            |                                 |
|-----------------------------------------|---------------------------------|
| <b>Ingredients</b>                      | <b>Quantity (g)</b>             |
| Risperidone                             | 1.0                             |
| Spray-dried mannitol                    | 77.5                            |
| Microcrystalline cellulose              | 15.0                            |
| Sodium croscarmellose                   | 1.5                             |
| Ammonium glycyrrhizinate                | 0.5                             |
| Aspartame                               | 2.0                             |
| Orange flavour                          | 1.5                             |
| Magnesium stearate                      | 1.0                             |
| <b>Parameters</b>                       | <b>Values</b>                   |
| Shape                                   | Round 7.5 mm,<br>flat, bevelled |
| Average weight (mg)                     | 102.1 (93.2-106.1)              |
| Hardness (N)                            | 21.5 (16-42)                    |
| Thickness (mm)                          | 2.01 (1.93-2.06)                |
| Tensile strength (N/mm <sup>2</sup> )   | 0.9                             |
| Friability (%)                          | 0.2                             |
| Apparent density (g/ml)                 | 1.17                            |
| <i>In vitro</i> disintegration time (s) | 19.7 (16-24)                    |
| <i>In vivo</i> disintegration time (s)  | 12-15                           |

5

#### **EXAMPLE 10**

A mixture of orally disintegrating tablets of fluoxetine was prepared, using the general process initially described and with the composition and results given in 10 Table X. The results obtained in the characterisation of the tablets are also given in Table X.

**Table X: Orally disintegrating tablets of 20 mg of fluoxetine**

| <b>Composition for 100 g</b>            |                             |
|-----------------------------------------|-----------------------------|
| <b>Ingredients</b>                      | <b>Quantity (g)</b>         |
| Fluoxetine hydrochloride                | 7.5                         |
| Spray-dried mannitol                    | 71.0                        |
| Microcrystalline cellulose              | 15.0                        |
| Sodium croscarmellose                   | 3.0                         |
| Ammonium glycyrrhizinate                | 0.3                         |
| Aspartame                               | 1.0                         |
| L-menthol                               | 0.2                         |
| Mint flavouring                         | 1.0                         |
| Magnesium stearate                      | 1.0                         |
| <b>Parameters</b>                       | <b>Values</b>               |
| Shape                                   | Round 13 mm, flat, bevelled |
| Average weight (mg)                     | 301.3 (298.2-304.1)         |
| Hardness (N)                            | 34 (29-37)                  |
| Thickness (mm)                          | 1.92                        |
| Tensile strength (N/mm <sup>2</sup> )   | 0.9                         |
| Friability (%)                          | 0.31                        |
| Apparent density (g/ml)                 | 1.18                        |
| <i>In vitro</i> disintegration time (s) | 32.4 (28-36)                |
| <i>In vivo</i> disintegration time (s)  | 19 (16-21)                  |

#### 5 EXAMPLE 11

A mixture of orally disintegrating tablets of paroxetine was prepared using the general process initially described and with the composition and results given in Table XI. The results obtained in the characterisation of the 10 tablets are also given in Table XI.

**Table XI: Orally disintegrating tablets of 20 mg of paroxetine**

| <b>Composition for 100 g</b>          |                             |
|---------------------------------------|-----------------------------|
| <b>Ingredients</b>                    | <b>Quantity (g)</b>         |
| Paroxetine hydrochloride hemihydrate  | 9.1                         |
| Potassium polacrilin                  | 9.1                         |
| Spray-dried mannitol                  | 67.6                        |
| Microcrystalline cellulose            | 10.0                        |
| Sodium croscarmellose                 | 0.5                         |
| Ammonium glycyrrhizinate              | 0.5                         |
| Aspartame                             | 1.0                         |
| L-menthol                             | 0.2                         |
| Mint flavouring                       | 1.0                         |
| Magnesium stearate                    | 1.0                         |
| <b>Parameters</b>                     | <b>Values</b>               |
| Shape                                 | Round 13 mm, flat, bevelled |
| Average weight (mg)                   | 302.1<br>(298.2-307.4)      |
| Hardness (N)                          | 31 (26-34)                  |
| Thickness (mm)                        | 1.98                        |
| Tensile strength (N/mm <sup>2</sup> ) | 0.8                         |
| Friability (%)                        | 0.19                        |
| Apparent density (g/ml)               | 1.15                        |
| In vitro disintegration time (s)      | 36.4 (33-40)                |
| In vivo disintegration time (s)       | 21 (18-24)                  |

5 Although the invention has been described in reference to the above specific embodiments, all modifications and changes that might be made by a skill man in the art, as routine practice, must be considered with in the scope of protection of the invention.

**CLAIMS**

1. Orally administered tablet that disintegrates quickly in the oral cavity in less than 30 seconds, comprising:

i) Spray-dried mannitol in a proportion of at least 59.5%;

ii) active ingredient in a proportion below or equal to 10%, as a fine powder in which at least 90% in weight of the active ingredient has a particle size less than 100  $\mu\text{m}$ ;

iii) Microcrystalline cellulose in a proportion from 10 to 18%, with an average particle size of approximately 50  $\mu\text{m}$  where at least 99% in weight of microcrystalline cellulose has a particle size below 250  $\mu\text{m}$ ;

iv) Sodium croscarmellose in a proportion from 1 to 4%; and

v) A lubricant agent in a proportion from 0.5 to 2% in weight,

where, unless specified otherwise, the percentages are expressed in weight of the total weight of the tablet.

2. Orally administered tablet according to claim 1, characterised in that it has a friability below 0.5% according to Ph. Eur. 2.9.7.,

3. Orally administered tablet according to claim 2, characterised in that it has a friability below 0.2% according to Ph. Eur. 2.9.7.

4. Orally administered tablet according to claim 1, characterised in that it has an apparent density from 1.1 to 1.3 g/ml.

5. Orally administered tablet according to claim 1, characterised in that it has a flavouring agent in a proportion from 0.5 to 2% in weight of the total weight of the tablet.

5

6. Orally administered tablet according to claim 5, characterised in that it has an artificial sweetener in a proportion from 0.5 to 2% in weight of the total weight of the tablet.

10

7. Orally administered tablet according to claim 1, characterised in that it has a humidity adsorbing agent in a proportion from 0.1 to 0.5% in weight of the total weight of the tablet.

15

8. Orally administered tablet according to claim 1, characterised in that it has an anti-adherent agent in a proportion from 0.5 to 2% in weight of the total weight of the tablet.

20

9. Orally administered tablet according to claim 1, characterised in that the proportion of insoluble elements is below 20% in weight of the total weight of the tablet.

25

10. Orally administered tablet according to any of previous claims, characterised in that it has a round shape, flat, bevelled with a thickness from 1,8 to 2.2 mm.

30

11. Orally administered tablet according to claim 10, characterised in that it disintegrates quickly in the oral cavity in less than 20 seconds.

12. Process for obtaining an orally administered  
35 tablet as defined in any of claims 1 to 11, characterised

in that it comprises the following steps:

- i) Sieving and mixing the components except for the lubricant agent;
- ii) Sieving the lubricant agent;
- 5      iii) Mixing of all the components; and
- iv) Direct compression of the final mixture.

13. Process for obtaining a tablet according to claim 12, characterised in that said final mixture has a  
10 flowability below or equal to 10 seconds according to Ph. Eur. 2.9.16.

14. Process for obtaining a tablet according to claim 12, characterised in that said final mixture has an  
15 ability to settle below or equal to 20 ml according to Ph. Eur. 2.9.15.

5

10

15

20




Fig.1

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/15 03/02446

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/00 A61K47/26 A61K47/38 A61K47/36

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                  | Relevant to claim No. |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Y          | WO 01 12161 A (NOVARTIS CONSUMER HEALTH SA<br>;MARTANI ROSA (FR))<br>22 February 2001 (2001-02-22)<br>page 11, line 12 - line 28<br>page 12, line 4<br>example 1<br><br>---<br>-/-- | 1-14                  |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* & \* document member of the same patent family

Date of the actual completion of the international search

2 October 2003

Date of mailing of the international search report

15/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Villa Riva, A

## INTERNATIONAL SEARCH REPORT

Internet Application No.  
PCT/IB 03/02446

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                       |
|------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Category *                                           | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Relevant to claim No. |
| Y                                                    | <p>NILSSON P ET AL: "PHYSICOCHEMICAL ASPECTS OF DRUG RELEASE V. THE IMPORTANCE OF SURFACE COVERAGE AND COMPACTION ON DRUG DISSOLUTION FROM ORDERED MIXTURES" INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 45, no. 1-2, 1988, pages 111-122, XP009018006<br/>ISSN: 0378-5173<br/>abstract<br/>page 112, right-hand column, line 26<br/>-left-hand column, last line<br/>table 4<br/>figure 2<br/>page 120, left-hand column, line 24<br/>-right-hand column, line 2</p>                                                                            | 1-14                  |
| Y                                                    | <p>MATTSSON S ET AL: "Formulation of high tensile strength rapidly disintegrating tablets: Evaluation of the effect of some binder properties" S.T.P. PHARMA SCIENCES 2001 FRANCE, vol. 11, no. 3, 2001, pages 211-220, XP009018012<br/>ISSN: 1157-1489<br/>abstract<br/>page 211, left-hand column, line 28 - last line<br/>page 211, right-hand column, line 30 -page 212, left-hand column, line 2<br/>page 212, right-hand column, line 6,22,23<br/>table 3<br/>page 217, Section 3.2<br/>figure 7<br/>page 219, right-hand column, line 28 - line 48</p> | 1-14                  |
| A                                                    | <p>US 5 904 937 A (VLADYKA JR RONALD S ET AL) 18 May 1999 (1999-05-18)<br/>example 6</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1-14                  |
| A                                                    | <p>US 5 686 107 A (RATNARAJ SHEILA ET AL) 11 November 1997 (1997-11-11)<br/>preparations 15AA, 3ASP, 7ASP</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1-14                  |

## INTERNATIONAL SEARCH REPORT

Internal Application No.   
 PCT/LB 03/02446

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---|---------------------|----------------------------|---------------------|
| WO 0112161                                | A | 22-02-2001          | AU 7275700 A               | 13-03-2001          |
|                                           |   |                     | CA 2380449 A1              | 22-02-2001          |
|                                           |   |                     | WO 0112161 A1              | 22-02-2001          |
|                                           |   |                     | EP 1202716 A1              | 08-05-2002          |
|                                           |   |                     | JP 2003506480 T            | 18-02-2003          |
|                                           |   |                     | TR 200200313 T2            | 22-04-2002          |
|                                           |   |                     | US 2002131998 A1           | 19-09-2002          |
| <hr/>                                     |   |                     |                            |                     |
| US 5904937                                | A | 18-05-1999          | AU 1063799 A               | 27-04-1999          |
|                                           |   |                     | BR 9812590 A               | 01-08-2000          |
|                                           |   |                     | CA 2303177 A1              | 15-04-1999          |
|                                           |   |                     | CN 1273527 T               | 15-11-2000          |
|                                           |   |                     | EP 1027038 A1              | 16-08-2000          |
|                                           |   |                     | JP 2001518491 T            | 16-10-2001          |
|                                           |   |                     | NO 20001670 A              | 22-05-2000          |
|                                           |   |                     | PL 339568 A1               | 18-12-2000          |
|                                           |   |                     | WO 9917748 A1              | 15-04-1999          |
| <hr/>                                     |   |                     |                            |                     |
| US 5686107                                | A | 11-11-1997          | NONE                       |                     |
| <hr/>                                     |   |                     |                            |                     |